Hemochromatosis (HFE) gene mutations in Brazilian chronic hemodialysis patients by Perícole, F.V. et al.
1321
Braz J Med Biol Res 38(9) 2005
Hemochromatosis gene mutations in chronic hemodialysis patients
Hemochromatosis (HFE) gene
mutations in Brazilian chronic
hemodialysis patients
Divisões de Nefrologia e de Hematologia, Departamento de Medicina Interna,
Faculdade de Ciências Médicas, Universidade Estadual de Campinas,
Campinas, SP, Brasil
F.V. Perícole,
M.A.V.R. Alves,
S.T.O. Saad and
F.F. Costa
Abstract
Patients with chronic renal insufficiency (CRI) have reduced hemo-
globin levels, mostly as a result of decreased kidney production of
erythropoietin, but the relation between renal insufficiency and the
magnitude of hemoglobin reduction has not been well defined. He-
reditary hemochromatosis is an inherited disorder of iron metabolism.
The importance of the association of hemochromatosis with treatment
for anemia among patients with CRI has not been well described. We
analyzed the frequency of the C282Y and H63D mutations in the HFE
gene in 201 Brazilian individuals with CRI undergoing hemodialysis.
The analysis of the effects of HFE mutations on iron metabolism and
anemia with biochemical parameters was possible in 118 patients of
this study (hemoglobin, hematocrit, ferritin levels, transferrin satura-
tion, and serum iron). A C282Y heterozygous mutation was found in
7/201 (3.4%) and H63D homozygous and heterozygous mutation
were found in 2/201 (1.0%) and 46/201 (22.9%), respectively. The
allelic frequencies of the HFE mutations (0.017 for C282Y mutation
and 0.124 for H63D mutation) did not differ between patients with
CRI and healthy controls. Regarding the biochemical parameters, no
differences were observed between HFE heterozygous and mutation-
negative patients, although ferritin levels were not higher among
patients with the H63D mutation (P = 0.08). From what we observed
in our study, C282Y/H63D HFE gene mutations are not related to
degrees of anemia or iron stores in CRI patients receiving intravenous
iron supplementation (P > 0.10). Nevertheless, the present data sug-
gest that the H63D mutation may have an important function as a
modulating factor of iron overload in these patients.
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Anemia associated with chronic renal in-
sufficiency (CRI) has clinical and public
health importance (1). Patients with CRI
have reduced hemoglobin levels, mostly as a
result of decreased kidney production of
erythropoietin, although the relation between
the degree of renal insufficiency and the
magnitude of hemoglobin reduction is not
well understood. The high efficacy and ben-
efit of recombinant human erythropoietin in
the treatment of renal anemia have been
documented in numerous studies, (1,2).
Absolute and functional iron deficiencies
are common in hemodialysis patients treated
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with recombinant human erythropoietin
(2,3). Maintaining normal iron homeostasis
is essential for the organism since both iron
deficiency and iron excess are associated
with cellular dysfunction (4). Ferritin is the
major iron storage protein, mostly in the
cells of the macrophage-monocyte system
(especially in the liver, spleen, bone mar-
row, and skeletal muscle) (5). There was a
good correlation between the small amount
of ferritin found in serum and body iron
stores (6).
Hereditary hemochromatosis (HH) is an
inherited disorder of iron metabolism, com-
mon among populations of Northern Euro-
pean origin, in which intestinal iron absorp-
tion is excessive irrespective of body iron
stores (7). In 1996, Feder et al. (8) described
two mutations in the HFE gene located on
chromosome 6 as one of the defects respon-
sible for hemochromatosis.
The mutation found to be associated with
HH was a single base change in exon 4,
resulting in the substitution of tyrosine for
cysteine at amino acid 282 of the unpro-
cessed protein (C282Y). The proportion of
HH patients homozygous for C282Y varies,
ranging from 64% in Italy to 100% in Aus-
tralia (9). The other is a missense mutation at
nucleotide 187 of the HFE open reading
frame, resulting in the substitution of histi-
dine for aspartate at amino acid 63 (H63D).
It is found in 15-40% of Caucasians and
H63D homozygosity leads to only a slight
increased risk for iron loading. Both muta-
tions are generally expressed only in ho-
mozygosity, but there are few studies con-
cerning the effect of these mutations on pa-
tients with CRI and their relation with sup-
plementation therapy with high doses of in-
travenous iron (10).
We determined the frequency of the
C282Y and H63D mutations in Brazilian
individuals with chronic renal insufficiency
undergoing hemodialysis and the effects of
HFE mutations, iron metabolism and ane-
mia.
We analyzed 201 patients with CRI un-
dergoing chronic hemodialysis at the Uni-
versity Hospital of Campinas, comprising
118 men (58.7%) and 83 women (41.3%).
Their mean age was 45.5 years (range 14-82
years). Ninety-one blood donors (50 men
and 41 women) were included as healthy
controls regardless of ethnic classification.
The study was approved by the Ethics Com-
mittee of the Hospital and all patients gave
written informed consent to participate
The C282Y and H63D mutations were
detected by restriction enzyme analysis of
PCR-amplified DNA extracted from periph-
eral blood leukocytes (11). The digested
products were run on 3.5% agarose gels and
stained with ethidium bromide.
The possible relationship between HFE
mutations and iron metabolism was deter-
mined using the hematological and biochemi-
cal parameters of 118 of the patients under
study (hemoglobin, hematocrit, ferritin lev-
els, transferrin saturation, and serum iron).
Data were analyzed statistically with the
Epi-Info 6.0 software using Fisher’s exact
test and the Student t-test, with the level of
significance set at P < 0.05.
Heterozygous C282Y mutation was found
in 7/201 patients (3.4%) and H63D homozy-
gous and heterozygous mutation were found
in 2/201 (1.0%) and 46/201 (22.9%), respec-
tively. The allelic frequencies of the HFE
mutations (0.017 for C282Y mutation and
0.124 for H63D mutation) did not differ
between patients with CRI and healthy con-
trols (0.011 for C282Y mutation and 0.098
for H63D mutation). There were no com-
pound heterozygous patients.
The biochemical and hematological pa-
rameters of 118 patients are presented in
Tables 1 and 2, divided according to geno-
type. No differences were observed between
C282Y HFE heterozygous and HFE normal
patients with CRI (Table 1). There was no
association between mutation and serum iron,
transferrin saturation, hemoglobin and hem-
atocrit levels (P > 0.10) for the H63D muta-
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tion (Table 2) but, as expected, there was a
relation between ferritin and transferrin satu-
ration (P < 0.001). Interestingly, in our study,
ferritin levels were not higher among pa-
tients with H63D mutation (P = 0.08). The
study of larger number of patients should
clarify this possibility. In addition, the high-
est serum ferritin level and transferrin satu-
ration were noticed in the only H63D ho-
mozygous patient analyzed. A previous study
from Italy with 132 patients with CRI on
dialysis also did not find a relation between
biochemical parameters and C282Y/H63D
mutations (12).
The results presented here indicate an
influence, not yet determined, of the H63D
mutation in patients with CRI. This mutation
appears to lead to only a slightly (~4-fold)
increased risk for iron loading when in ho-
mozygosity (9), but it may be more impor-
tant among CRI patients probably due to
supplementation with high doses of intrave-
nous iron. The patients with the mutation
would be more susceptible to an iron over-
load because of the genetic susceptibility
and excessive doses of intravenous iron ad-
ministered to CRI patients, as previously
proposed (13,14).
Taken together, the present data do not
determine if the H63D mutation is a factor
modifying the iron balance among patients
with CRI undergoing hemodialysis and in-
travenous iron therapy, therefore suggesting
Table 1. Biochemical parameters of 118 patients with chronic renal insufficiency,
classified by C282Y genotype in the HFE gene.
C282Y mutation C282Y negative C282Y heterozygous
Serum iron (µg/dL) 74.5 ± 45.27 (88) 64 ± 29.46 (3)
Ferritin (ng/mL) 743.9 ± 637.44 (90) 207 ± 204.41 (3)
Transferrin saturation (%) 32 ± 17.80 (73) 26.4 (1)
Hb (g/dL) 10.7 ± 1.92 (97) 10.1 ± 2.85 (4)
Ht (%) 32.6 ± 5.88 (96) 30.3 ± 9.15 (4)
Data are reported as median ± SD. The number of patients analyzed is given in
parentheses. There was no statistically significant difference between groups (chi-
square test).
Table 2. Biochemical parameters of 118 patients with chronic renal insufficiency,
classified by H63D genotype in the HFE gene.
H63D mutation H63D H63D H63D
negative heterozygous homozygous
Serum iron (µg/dL) 76.5 ± 47.31 (72) 62 ± 24.11 (19) 153 (1)
Ferritin (ng/mL) 703 ± 591.07 (75) 1004.7 ± 667.24 (18) 2493 (1)
Transferrin saturation (%) 31.6 ± 17.94 (59) 28 ± 15.64 (15) 68.9 (1)
Hb (g/dL) 10.7 ± 2.07 (80) 10.7 ± 1.41 (21) 9.1 (1)
Ht (%) 32.4 ± 6.22 (78) 32.8 ± 4.94 (22) 28 (1)
Data are reported as median ± SD. The number of patients analyzed is given in
parentheses. There was no statistically significant difference between groups (chi-
square test).
the need of a further multicentric study in
order to clarify this possibility. If this hypo-
thesis is confirmed, patients with H63D
mutation should be closely monitored for
ferritin in order to prevent iron overload.
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